A Physician Research Group Is Evaluating the Efficacy of a New

A physician research group is evaluating the efficacy of a new lipid-lowering drug, Superstatin, which is being marketed directly to consumers as a groundbreaking new therapy to prevent heart attacks.  The drug manufacturer claims that the drug is more effective than existing hypolipidemic agents for primary prevention of myocardial infarction.  Results of a 5-year, randomized, double-blinded, controlled study to evaluate the efficacy of Superstatin are shown below. Compared to the control medication, how many patients need to be treated with Superstatin to prevent one additional myocardial infarction?

A) 2
B) 5
C) 23
D) 48
E) 67
F) 92
G) 100

Correct Answer:

Verified

Unlock this answer now
Get Access to more Verified Answers free of charge

Access For Free